$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
几乎所有多发性骨髓瘤患病者都会选择马法兰(melphalan)
2025-10-19 11:44:20
Check Details
血液肿瘤新药XPO1抑制剂塞利尼索获批上市!
2025-10-19 11:44:20
Check Details
马法兰的正确使用方法是怎样的?有什么副作用?
2025-10-19 11:44:20
Check Details
展望:多发性骨髓瘤的在研治疗方案
2025-10-19 11:44:20
Check Details
多发性骨髓瘤药物卡非佐米中国获批上市!
2025-10-19 11:44:20
Check Details
卡非佐米是什么药?哪里能买到卡非佐米?
2025-10-19 11:44:20
Check Details
普乐沙福plerixafor最大剂量是多少?用多久会耐药
2025-10-19 11:44:20
Check Details
FDA批准Cilta-Cel治疗复发/难治性多发性骨髓瘤
2025-10-19 11:44:20
Check Details
伊沙佐米是化疗药物还是靶向药物?
2025-10-19 11:44:20
Check Details
泊马度胺Pomalidomide的疗效好不好?副作用多不多
2025-10-19 11:44:20
Check Details
治疗多发性骨髓瘤新药:帕比司他
2025-10-19 11:44:20
Check Details
帕比司他的使用方法和副作用你都知道吗?
2025-10-19 11:44:20
Check Details
1
2
...
1162
1163
1164
1165
1166
1167
1168
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
2
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
3
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
4
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
5
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
6
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
7
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
8
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
9
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
12
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance